A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Inclusion Criteria:

• Male or female, ≥ 18 years of age (20 years or older in Japan)
• Clinical history consistent with non-cystic fibrosis bronchiectasis (cough, chronic sputum production and/or recurrent respiratory infections) that is confirmed by chest computerized tomography (CT) scan
• At least 2 pulmonary exacerbations defined by need for antibiotic prescription by a physician for the signs and symptoms of respiratory infections in the past 12 months before the Screening Visit
• Women must be post-menopausal (defined as no menses for 12 months without an alternative medical cause), surgically sterile, or using highly effective double barrier contraception (i.e., methods that in combination achieve <1% unintended pregnancy rates per year) from Day 1 to at least 90 days after the last dose
• Male participants with female partners of childbearing potential must be using effective contraception from Day 1 to at least 90 days after the last dose

Exclusion Criteria:

• A primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma as judged by the Investigator
• Bronchiectasis due to cystic fibrosis
• Current smokers as defined per Centers for Disease Control (CDC)
• Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections
• Known history of human immunodeficiency virus (HIV) infection
• Currently being treated for nontuberculous mycobacteria (NTM) lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis (TB)
• Receiving medications or therapy that are prohibited as concomitant medications
• Suffering an exacerbation 4 weeks before Screening or during the Screening period
• History of alcohol or drug abuse within 6 months prior to the Screening Visit